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Abstract
Objective: The primary goal of this exploratory study was to obtain data that could lead to evidence-based dosing strategies
for lithium in children and adolescents suffering from bipolar I disorder.
Methods: Outpatients aged 7–17 years meeting Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diag-
nostic criteria for bipolar I disorder (manic or mixed) were eligible for 8 weeks of open label treatment with lithium in one of
three dosing arms. In Arm I, participants began treatment at a dose of 300 mg of lithium twice daily. The starting dose of
lithium in Arms II and III was 300 mg thrice daily. Patients in Arms I and II could have their dose increased by 300 mg/day,
depending on clinical response, at weekly visits. Patients in Arm III also had mid-week telephone interviews after which they
could also have their dose of lithium increased by 300 mg per day. Youths weighing <30 kg were automatically assigned to
Arm I, whereas youths weighing30 kg were randomly assigned to Arm I, II, or III. Randomization was balanced by age (7–
11 years, 12–17 years) and sex in approximately equal numbers. A priori response criteria were defined as a Clinical Global
Impressions-Improvement scale score of 2 and a 50% decrease from baseline on the Young Mania Rating Scale.
Results: Of the 61 youths [32 males (52.5%)] who received open-label lithium, 60 youths completed at least 1 week of
treatment and returned for a postbaseline assessment. Most patients had a50% improvement in Young Mania Rating Scale
score, and more than half of the patients (58%) achieved response. Overall, lithium was well tolerated. All three treatment
arms had similar effectiveness, side effect profiles, and tolerability of lithium.
Conclusions: On the basis of these results, a dosing strategy in which pediatric patients begin lithium at a dose of 300 mg
thrice daily (with an additional 300 mg increase during the first week), followed by 300 mg weekly increases until a priori
stopping criteria are met, will be used in an upcoming randomized, placebo-controlled trial.
Introduction
Recently, bipolar disorder has become a clinical entity thatis becoming better characterized in children and adolescents
(Findling et al. 2001; Kowatch et al. 2005; McClellan et al. 2007).
Because of the chronicity and severity of this illness (Geller et al.
2004; Biederman et al. 2005; Birmaher et al. 2006), it is important
that safe and effective treatments for pediatric bipolar disorder be
developed.
Lithium has been known to be an effective treatment option for
adults with bipolar disorder for over 50 years (Cade 2000), and
lithium’s potential benefits in adults have been well documented
(reviewed by Goodwin 2002; Muzina and Calabrese 2005; Thase
and Denko 2008). Despite the fact that lithium is a benchmark
treatment for bipolarity in adults, prior lithium research in pediatric
bipolarity has generally lacked methodological rigor (Findling and
Pavuluri 2008). Most prior studies that have examined the biodis-
position of lithium in pediatric patients, or that have sought to
develop evidence-based dosing strategies for lithium in children
and adolescents have generally recruited small sample sizes
(Vitiello et al. 1988; Hagino et al. 1998). However, previous
pharmacokinetic work performed by our group suggests that the
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dosing interval for lithium that is used in adults may be suitable
when treating children and adolescents with this agent (Findling
et al. 2010). Additional research that has been performed in the
young has suggested that lithium may produce salutary effects
when prescribed to pediatric-aged patients. Most likely owing to
the fact that definitive dosing studies have not been performed with
lithium in children and adolescents, dosing paradigms for lithium
frequently have varied across clinical trials in youths (Findling and
Pavuluri 2008).
As the result of a Written Request being issued by the Food and
Drug Administration (FDA), the work described herein was con-
ducted under the auspices of a National Institute of Child Health
and Human Development (NICHD)–supported contract. The pur-
pose of that contract is to support research that will comprehen-
sively test lithium as a potential treatment for pediatric patients
suffering from bipolar I disorder (BP-I) (Findling et al. 2008). The
primary goal of this exploratory study was to obtain data that could
lead to evidence-based dosing strategies for lithium in children and
adolescents suffering from BP-I. The decision to employ a sample
size of *20 patients being enrolled into each arm was based upon
specific directions from the FDA’s Written Request.
As part of this endeavor, the following parameters were exam-
ined: (1) the range of therapeutic lithium blood concentrations, (2)
the safety and effectiveness of different starting doses of lithium,
and (3) the risks and benefits associated with different rates of
lithium dose escalation.
Methods
The Institutional Review Boards for Human Investigation at
each of the seven participating sites approved the procedures of this
study. The parent/guardians of all study participants provided
written informed consent, and all youths provided written assent
before any study-related procedures were performed. In addition,
an independent Data Safety and Monitoring Board reviewed the
progress of this clinical trial.
Study overview
This was an 8-week study with three parallel arms (Arm I, Arm
II, and Arm III). Medically healthy children and adolescents aged
7–17 years suffering from a manic or mixed episode were eligible
to participate. Additional inclusion and exclusion criteria are de-
scribed in Table 1. After a screening period, participants were seen
at baseline and weekly thereafter. In this study, lithium was pro-
vided as 300 mg lithium carbonate capsules.
Screening procedures
Once informed consent and assent were obtained, youths par-
ticipated in a screening phase to determine participant eligibility.
Information about inclusion and exclusion criteria was collected,
and pretreatment laboratories and safety measures were obtained.
The screening period was 3–28 days. However, if the patient was
currently receiving fluoxetine at the initial assessment, the
screening period was extended to last up to 6 weeks (see below).
Enrollment to Arm I and Arm II
At the start of the trial, only enrollment into the first two dosing
initiation arms (Arm I and Arm II) was allowed. The purpose of this
first portion of the trial was to determine an evidence-based starting
dose for lithium.
In Arm I, participants began treatment at a dose of 300 mg of
lithium twice daily. The starting dose of lithium in Arm II was
300 mg thrice daily. To ensure participant safety, youths who
weighed <30 kg were automatically assigned to Arm I, with a
600 mg starting dose, and could not be enrolled into any other
treatment arm. At the time this study was designed, there were
limited data about starting lithium treatment at a dose above 30 mg/
kg/day (Weller et al. 1986). In addition, a recent prior study of
lithium in pediatric bipolar disorder had mean final doses that were
<30 mg/kg/day (Findling et al. 2003).
The first participants weighing 30 kg or more were randomly
assigned to either Arm I or II, with randomization being balanced
by age (7–11 years, 12–17 years) and sex in approximately equal
numbers. After receiving this starting dose, participants who were
randomized to Arms I and II were to have their doses of lithium
increased by 300 mg each week unless one or more of four different
‘‘stopping’’ criteria were met (Table 2). It should be noted that a
patient’s dose of lithium could be reduced at any time to address
concerns about lithium tolerability. However, youths who could not
Table 1. Inclusion/Exclusion Criteria
Inclusion Exclusion
Good physical health Allergy to or intolerance for lithium
Capable of swallowing study medication (lithium carbonate
capsules) whole
Unstable medical illness that might be adversely affected by
lithium
Wechsler Abbreviated Scales of Intelligence (WASI)
Vocabulary and Matrix Reasoning Subscales
(Wechsler 1999) intelligence quotient of 70 or greater
Comorbid diagnosis of: Schizophrenia, schizoaffective disorder, a
pervasive developmental disorder, anorexia nervosa, bulimia
nervosa, substance dependence, or obsessive-compulsive dis-
order
Comorbid psychiatric diagnosis of attention-deficit/
hyperactivity disorder or a disruptive behavior
disorder (allowed, not required)
Concomitant nonstimulant psychotropic agents within the
preceding 2 weeks; stimulant use within the preceding week;
fluoxetine or depot antipsychotics in the past month
Negative urine toxicology screen (if initial screen
positive, may be retested 1 to 3 weeks later)
Psychiatric hospitalization for psychosis or serious homicidal/
serious suicidal ideation within 1 month of screening
Sexually active women using adequate forms of birth control Current active hallucinations or delusions
Negative urine and serum pregnancy tests for sexually active
women
Symptoms of mania attributable to a general medical condition or
secondary to use of medications
Washout of exclusion medications during screening period and
before administration of lithium
Initiation of concomitant psychotherapeutic treatments within
4 weeks before screening
No clinically significant abnormalities in ECG and blood work Pregnant or lactating women
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tolerate a minimum lithium dose of 600 mg per day were to be
withdrawn.
The decision to test a 600 mg versus a 900 mg per day starting
dose was based on a typical starting dose of 900 mg for adults with
bipolar disorder (Bowden et al. 1994). As children and adolescents
are generally smaller than adults, and potentially more vulnerable
to lithium-related adverse events (AEs), it was believed that it
would be important to examine whether youths could tolerate an
adult-sized starting dose of lithium.
Opening enrollment into Arm III
Once it was determined that a starting dose of 900 mg of lithium
per day with weekly increases was tolerable by at least 8 out of first
10 patients who completed 8 weeks of lithium treatment, ran-
domization into Arm III became possible. Once Arm III became
open for enrollment, participants weighing 30 kg or greater were
randomly assigned (balanced for age and sex as noted above) to
receive treatment in Arm I, II, or III until each arm was filled.
Similar to participants in Arm II, participants in Arm III began
treatment with a starting dose of lithium of 300 mg of lithium ad-
ministered thrice daily and were to have their dose of lithium in-
creased by 300 mg per day at the weekly study visits until one or
more stopping criteria were met. However, based upon the strategy
employed by Bowden et al. (1994), all participants in Arm III could
also have their dose of lithium increased by 300 mg per day after
regularly scheduled mid-week telephone interviews were con-
ducted with the participant and their parent/guardian. These tele-
phone calls, during which dosing decisions were made based on
salutary effects and tolerability, were conducted at the mid-point of
each week until the participant met one or more stopping criteria for
dose escalation. Thus, the purpose of Arm III was determine
whether or not twice weekly increases in lithium dosing could
safely increase the rapidity with which the patient achieved their
therapeutic dose of lithium.
Dose escalation
As mentioned above, the dose of lithium the participants were
receiving was to be increased by 300 mg at the weekly study visits (as
well as after the mid-week telephone interviews in Arm III) unless
one or more of the stopping criteria for dose escalation were reached.
All scheduled study visits (including the mid-week telephone calls,
as noted below) were to occur within a 2 day window.
For participants who were enrolled in Arm III, their dose of
lithium was to be increased after the mid-week telephone call was
conducted [on days 3, 10, 17, and 24 (2 days)] as well as after the
weekly study visits. During these mid-week telephone calls, the
prescribing clinician interviewed the patient’s parent/guardian, and
as developmentally appropriate, the patient. The clinicians dis-
cussed medication adherence, global impressions of clinical re-
sponse, and AEs during these telephone calls. Unless there were
dose limiting AEs, clinical response (defined as Clinical Global
Impressions-Improvement (CGI-I) (NIMH 1985) score of2 and a
50% decrease in Young Mania Rating Scale (YMRS) (Young et al.
1978) score from baseline assessment), and adequate medication
adherence (see below), the participant was to have their daily
lithium dose increased by 300 mg.
The maximum daily weight-adjusted dose for lithium was set at
40 mg/kg/day. As noted above, a recent study that flexibly dosed
lithium had mean daily doses of lithium that were generally
<30 mg/kg/day (Findling et al. 2003). Thus, it was believed that
this maximum weight adjusted dose would be an important safe-
guard for study participants.
Typically, the target maximum lithium serum concentration in
adults is 1.3 mEq/L, with 1.5 mEq/L representing the lower limit
for toxicity (Amdisen 1980). For this study, 1.4 mEq/L was chosen
as the maximum serum lithium concentration above which further
dose increases could not occur. This concentration was selected
based on several observations. First and foremost, with 1.5 mEq/L
reportedly being the lower limit of lithium toxicity in adults, ex-
ceeding that concentration in children would have raised concerns
about participant safety.
Prior lithium studies in children and adolescents with bipolar
disorder had target lithium blood and serum concentrations sub-
stantially below 1.4 mEq/L. For example, a trial in which children
and adolescents were treated with risperidone in combination with
either lithium or divalproex sodium used a target serum level of
0.6–1.0 mEq/L (Pavuluri et al. 2004). Similarly, another combi-
nation therapy trial’s (lithium plus divalproex sodium) target blood
level was 0.6–1.2 mEq/L (Findling et al. 2003). Two studies of
lithium monotherapy, one open-label and one double-blind,
placebo-controlled, used target serum levels of 0.6–1.2 mEq/L
(Kafantaris et al. 2003) and 0.8–1.2 mEq/L (Kowatch et al. 2007).
However, prior work with lithium monotherapy also suggested the
possibility that lithium may have been under-dosed in prior trials.
In prior research that tested lithium carbonate, youths overall ap-
pear to receive benefit from lithium monotherapy treatment, but
generally neither achieve nor maintain remission with lithium
monotherapy.
Daily dosing of lithium
As lithium is typically dosed three times daily in adults (FDA
2003), the lithium dose for this study was divided thrice daily
(morning, after school, and evening). No dose at the three different
daily administration time points differed from each other by
>300 mg. To allow for the monitoring of potential treatment-
emergent adverse events (TEAEs) during periods of wakefulness, if
doses were unequal, the highest dose was given in the morning.
Trough lithium serum concentrations were obtained weekly.
Study participants
Outpatient youths aged between 7 and 17 years of age were
eligible. To be enrolled, participants had to meet Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (American
Psychiatric Association 1994), criteria for BP-I, currently in a
manic or mixed episode and without active psychotic symptoms,
based on a psychiatric interview by a child and adolescent psy-
chiatrist. In addition, a trained interviewer administered the Sche-
dule for Affective Disorders and Schizophrenia for School-Age
Table 2. Stopping Criteria for Dose Escalation
(1) The participant achieved therapeutic response: CGI-I Scale
score of 2 and a 50% decrease in YMRS score from baseline
assessment
(2) The youth experienced/reported adverse events that had a
significant impact on functioning and was putatively due to
lithium treatment
(3) The lithium dose exceeded 40 mg/kg/day
(4) The patient’s current serum lithium concentration was expected
to be greater than 1.4 mEq/L
CGI-I¼Clinical Global Impressions-Improvement; YMRS¼Young
Mania Rating Scale.
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Children-Present and Lifetime Version (Kaufman et al. 1997) to
confirm the diagnosis of BP-I. Participants also needed to receive a
score of 20 or greater on the YMRS at screening and baseline.
Psychometric measures
Beginning at baseline, weekly psychometric assessments in-
cluded the YMRS, Children’s Depression Rating Scale Revised
(Poznanski et al. 1984), the CGI-I, and the Clinical Global Im-
pressions-Severity (CGI-S) Scale (NIMH 1985). The Suicide Se-
verity Rating Scale (Posner et al. 2007) was also completed weekly.
The a priori primary outcome measure was the change from baseline
to the end of 8 weeks in the summary/rater assessment of the YMRS.
At weeks 4 and 8, the following additional measures were
completed: Parent General Behavior Inventory-10 Item Mania
Scale (Youngstrom et al. 2008), Children’s Global Assessment
Scale (Shaffer et al. 1983), Child Mania Rating Scale-Parent
(Pavuluri et al. 2006), Nisonger Child Behavior Rating Form-Ty-
pical IQ Version (Aman et al. 2008), Irritability, Depression, and
Anxiety Scale (Snaith et al. 1978), attention-deficit/hyperactivity
disorder Rating Scale-IV (DuPaul 1998), Brief Psychiatric Rating
Scale (BPRS) (Hughes et al. 2001), Pediatric Anxiety Rating Scale
(The Research Units on Pediatric Psychopharmacology Anxiety
Study Group 2002). The Social Adjustment Inventory for Children
and Adolescents ( John et al. 1987), Caregiver Strain Questionnaire
(Brannan et al. 1997), Family Environment Scale (Moos and Moos
1984), and Drug Use Screening Inventory (Tarter and Hegedus
1991) were obtained at week 8.
Response criteria
At the end of study participation, patients’ status was deter-
mined. Criteria for ‘‘Response’’ are listed above. ‘‘Partial Re-
sponse’’ was defined a priori as having a YMRS reduction of
25%–49% from baseline assessment and a CGI-I 3. ‘‘Non-
response’’ was defined a priori as having a YMRS reduction of
<25% from baseline assessment or a CGI-I 4, or an inability to
tolerate a dose of 600 mg/day of lithium.
AE monitoring
Patients were monitored for the presence of TEAEs using the
Side Effects Form for Children and Adolescents (SEFCA) (Klein
et al. 1994), the Neurological Examination for Lithium (NELi)
(Findling et al. 2008), and the Neurological Rating Scale (NRS)
(Simpson and Angus 1970) at baseline and each subsequent,
weekly study visit. A 13-item expanded version of the 10-item NRS
was used in this study to assess for potential additional extrapyra-
midal side effects. These additional items are (1) cogwheeling; (2)
acute dystonic reaction; and (3) subjective sense of stiffness.
The SEFCA is a 54-item scale that rates both the frequency and
severity of TEAEs that commonly occur in pediatric psychophar-
macology trials. The NELi, administered by a study physician,
measured the presence/absence of hand tremors as well as diffi-
culties with the finger-nose test, tandem walk, gait, grip strength,
and the Romberg Test. The NRS, also administered by a physician,
assessed for additional neurological adverse effects. In addition,
youths and their parents/guardians were also asked about any other
potential AEs not asked about in the aforementioned instruments in
an open-ended fashion.
Items from the SEFCA, NELi, NRS, or open-ended inquiry that
were reported as being present at study visits were documented.
The study physician who conducted the visit determined whether or
not what was reported constituted an AE. The intensity or severity
of AEs was graded as follows: Mild (awareness of sign of symptom,
but easily tolerated; not expected to have a clinically significant
effect on the subject’s overall health and well being; not likely to
require medical attention); moderate (discomfort enough to cause
interference with usual activity or affects clinical status; may re-
quire medical intervention); and severe (incapacitating or signifi-
cantly affecting clinical status; likely requires medical intervention
and/or close follow-up). Further, the study physician assessed the
relationship of AEs to the study medication using the following
definitions: Probable (a clinical event, including a laboratory test
abnormality, in which a relationship to the study drug seems
probable because of such factors and consistency with known side
effects of the drug, a clear temporal association with the use of the
drug, improvement upon withdrawal of the drug, lack of alternative
explanations for the experience, or other factors); possible (a
clinical event, including a laboratory test abnormality, with a rea-
sonable time sequence to administration of the study drug, but
which could not be explained by concurrent disease or other drugs
or chemicals); and unlikely (a clinical event, including a laboratory
test abnormality, with a temporal relationship to study drug ad-
ministration, which makes a causal relationship improbable and in
which other factors suggesting an alternative etiology exist; such
factors known include a known relationship of the adverse expe-
rience to concomitant medication, the subject’s disease state, or
environmental factors, including common infections and diseases).
Laboratory and other safety assessments
Before receiving study medications, participants received a
fasting comprehensive chemistry profile (measuring blood con-
centrations of glucose, urea nitrogen, sodium, potassium, chloride,
bicarbonate, calcium, phosphorus, magnesium, creatinine, creati-
nine kinase, uric acid, total protein, direct and total bilirubin, al-
bumin, alkaline phosphatase, alanine aminotransferase, aspartate
aminotransferase, and gamma glutamyl transferase, complete
blood count with differential, coagulation function (measuring
prothrombin time, partial thromboplastin time, and fibrinogen),
lipid profile (measuring total cholesterol, triglycerides, high density
lipoproteins, low density lipoproteins, and cholesterol/high density
lipoprotein ratio), thyroid profile (measuring thyroid stimulating
hormone (TSH), triiodothyronine, thyroxine, and antithyroglobulin
and antithyroidperoxidase antibodies), urinalysis, and urine toxi-
cology screen. Additionally, women of child-bearing potential re-
ceived a urine and serum pregnancy test.
A chemistry profile, complete blood count and differential, urine
toxicology screen, and urinalysis were obtained at weeks 2, 4, and
8. Thyroid functioning (TSH, triiodothyronine, thyroxine, and an-
tithyroglobulin and antithyroidperoxidase antibodies) were ob-
tained at weeks 4 and 8. An ECG and a repeated height were also
measured at week 8. Blood pressure, pulse, and weight were also
obtained at each of the weekly study visits.
Medication adherence
Patients were asked to complete a lithium dosing diary; the
dosing diaries and study medication were collected at each visit.
Medication adherence was assessed by comparing the actual
number of capsules returned and the expected number of capsules
returned, and by the dosing diary. Additionally, medication com-
pliance was assessed by the review of the lithium trough serum
levels. Patients who missed>40% of the medication doses between
two appointments were discontinued from the study.
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Statistical methods
Descriptive statistics are provided for all consented patients who
received at least one dose of study medication by treatment group
(Arms I, II, and III). Continuous, quantitative variable summaries
include the number of patients, mean, standard deviation, median,
and ranges (minimum and maximum). Where applicable (primarily
for mean change from baseline), 95% confidence intervals are
provided. Categorical, qualitative variable summaries include the
frequency and percentage of patients who were in the particular
category. Within-group t-tests were used to determine the signifi-
cance of the mean change from baseline values (are mean values
significantly different from zero). Last observation carried forward
(LOCF) methods were implemented for summarization and anal-
ysis of change from baseline values for efficacy parameters. The
level of significance was set at 0.05 for all analyses. Due to the
exploratory nature of this trial, the alpha level for statistical sig-
nificance was not adjusted for the multiple comparisons performed.
All data summaries and statistical analyses were generated using
SAS software, Version 8.2 (or later).
Results
Study participants
One hundred five patients were screened for possible treatment
with lithium under the auspices of this clinical trial. Participant
accountability is summarized in Figure 1.
Of the 61 patients who received study medications, 60 youths
completed at least 1 week of treatment and returned for a post-
baseline assessment. Eight out of the first 10 patients in Arm II
completed 8 weeks of treatment and were determined to have tol-
erated the study drug; as a result, randomization into Arm III be-
came possible. Descriptive information for the 60 patients who both
received study medication and completed 1 week of treatment is
summarized in Table 3.
Lithium dosing
Of the 60 patients who both received study medication and
completed 1 week of treatment, 57 provided reliable dosing data.
For these 57 patients, the mean total daily dose was 1500.0 (400.9)
mg, whereas the mean weight-adjusted total daily dose was 29.1
(8.0) mg/kg/day. The mean serum concentration at the end of open
label treatment/end of study was 1.05 (0.39) mEq/L (range: 0.27–
2.08 mEq/L). Additional lithium dosing data by treatment arm are
presented in Table 4.
Of the 18 patients who participated in Arm III and provided
reliable data, 11 (61.1%) had upward dosing adjustments made
during the middle of the first week of treatment. However, only 5
(27.8%) had dosing increases made in the middle of the second
week of treatment that were subsequently maintained.
Symptomatic response
A summary of the overall and end of study measures across all
three treatment arms are provided in Table 5. The analysis of the
CGI-I (overall illness) status at the end of the study showed that
most patients (42 patients; 70%) were either very much improved
or were much improved on treatment. End of week 8/ET/LOCF
scores on the CGI-I across treatment arms are displayed in Figure 2.
The YMRS summary percentage improvement showed that more
than half of patients (37 patients; 61.7%) had a50% improvement
in their YMRS summary score. Response status at the end of the
study showed that more than half of patients (35 patients; 58.3%)
had response (50% reduction in YMRS summary score and CGI-I
score equal to 1 or 2). Remission status at the end of the study
showed the majority of patients (43 patients; 71.7%) were not in
remission (YMRS summary score >12 or CGI-S >2).
Medication tolerability
No deaths occurred in this study. Fifty-nine out of 60 patients
experienced at least one TEAE during study participation. Nine-
teen patients (31.7%) experienced a TEAE that was considered to
be possibly related to lithium, and 37 patients (61.7%) experi-
enced a TEAE that was considered to be probably related. Serious
TEAEs were experienced by a total of 6 patients (10.0%), only 1
of which (suicidal ideation) was considered to be possibly or
probably related to lithium. A total of 3 patients (5.0%) dis-
continued study medication due to a TEAE. A description of AE
Did not complete open label 
treatment (N=5) 
Reason for discontinuation: 
Adverse event (self-injurious 
behavior): N=1 
Adverse event (suicidal  
ideation): N=1 
Lack of efficacy: N=1 
Lost to follow-up: N=1 
Protocol noncompliance: N=1






Did not complete open 
label treatment (N=8) 
Reason for discontinuation: 
Adverse event (difficulty 
with memory): N=1 
Investigator decision: N=1 
Lack of efficacy: N=1 
Withdrew consent: N=5 




Did not complete open label 
treatment (N=7) 
Reason for discontinuation: 
Investigator decision: N=1 
Lack of efficacy: N=2 
Protocol noncompliance: N=3 
Withdrew consent: N=1 
Completed open label 
treatment (N=12) 
FIG. 1. Participant accountability.
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Table 3. Baseline Demographics
Treatment Arm
Arm I Arm II Arm III Total participants
(n¼ 20) (n¼ 21) (n¼ 19) (n¼ 60)
Age at randomization, years
Mean (SD) 11.7 (2.7) 12.5 (2.4) 13.5 (3.1) 12.6 (2.8)
Median 12.4 12.2 14.8 12.8
Range 7.9–15.7 8.5–17.7 8.7–17.5 7.9–17.7
Sex (male) 11 (55.0%) 9 (42.9%) 11 (57.9%) 31 (51.7%)
Race
Caucasian 14 (70.0%) 19 (90.5%) 14 (73.7%) 47 (78.3%)
African American 4 (20.0%) 2 (9.5%) 5 (26.3%) 11 (18.3%)
Caucasian/African American 2 (10.0%) 0 0 2 (3.3%)
Age of onset of bipolar disorder, years
Mean (SD) 8.1 (2.8) 9.9 (3.1) 10.0 (3.7) 9.3 (3.3)
Median 7.8 10.3 9.3 9.2
Range 2.0–12.8 4.0–16.0 3.3–17.0 2.0–17.0
Mood state at study entry
Manic 10 (50.0%) 9 (42.9%) 4 (21.1%) 23 (38.3%)
Mixed 10 (50.0%) 12 (57.1%) 15 (78.9%) 37 (60.7%)
Length of bipolar disorder illness, years
Mean (SD) 3.7 (2.7) 2.7 (1.7) 3.5 (3.2) 3.3 (2.6)
Median 2.9 2.5 2.3 2.5
Range 0.4–9.1 0.3–6.2 0.4–12.1 0.3–12.1
Psychiatric co-morbidity
Any ADHDa 16 (80.0%) 15 (71.4%) 12 (63.2%) 43 (71.7%)
Any disruptive behavior disorderb 3 (15.0%) 6 (27.3%) 6 (31.6%) 15 (25.0%)
Any anxiety disorderc 4 (20.0%) 6 (28.6%) 2 (10.5%) 12 (20.0%)
Participant length of study participation (days)
Mean (SD) 53.2 (12.8) 48.8 (14.5) 51.0 (17.4) 50.9 (14.8)
Median 57 56 56 56
Range 15–59 20–61 13–78 13–78
aADHD, attention-deficit/hyperactivity disorder; ADHD-combined; ADHD-inattentive; ADHD-hyperactive/impulsive; ADHD-not otherwise specified
(NOS).
boppositional defiant disorder; conduct disorder.
cgeneralized anxiety disorder; separation anxiety disorder; social phobia; specific phobia; panic disorder; post-traumatic stress disorder; anxiety
disorder-not otherwise specified (NOS). Note: no patients met diagnostic criteria for co-morbid obsessive compulsive disorder.
Table 4. Lithium Dosing and Serum Levels
Treatment Arm
Mean (SD) Arm I Arm II Arm III Total participants
Median (Range) (n¼ 20) (n¼ 19) (n¼ 18) (n¼ 57a)
























































aThree of the 60 patients who received study medication and completed 1 week of treatment were considered to be unreliable reporters; therefore,
dosing data for these patients are not included in these analyses.
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Table 5. Mean Outcome Measure Scores by Treatment Group
Treatment Arm
Arm I Arm II Arm III Total participants
Measure (n¼ 20) (n¼ 21) (n¼ 19) (n¼ 60)
YMRS
Baseline score Mean (SD) 31.3 (5.4) 30.3 (5.0) 29.5 (6.0) 30.3 (5.4)
EOS score Mean (SD) 14.0 (8.3) 12.1 (6.2) 14.2 (11.27) 13.4 (8.6)
Change score Mean (SD) 17.3 (7.2) 18.1 (8.4) 15.3 (10.9) 17.0 (8.9)
p< 0.0001
CDRS-R
Baseline score Mean (SD) 40.0 (7.6) 39.4 (13.0) 36.3 (12.8) 38.6 (11.3)
EOS score Mean (SD) 28.5 (9.7) 28.0 (8.9) 25.5 (6.4) 27.4 (8.4)
Change score Mean (SD) 11.5 (12.2) 11.3 (12.2) 10.8 (12.9) 11.2 (12.2)
p< 0.0001
CGAS
Baseline score Mean (SD) 47.5 (5.6) 50.8 (5.9) 49.6 (6.6) 49.3 (6.1)
EOS score Mean (SD) 62.9 (13.6) 65.2 (13.0) 64.7 (16.3) 64.3 (14.1)
Change score Mean (SD) 15.4 (11.3) 14.5 (11.2) 15.3 (14.1) 15.1 (12.0)
p< 0.0001
CGI-S (Mania)
Baseline score Mean (SD) 4.6 (0.6) 4.7 (0.7) 4.7 (0.7) 4.7 (0.7)
EOS score Mean (SD) 2.8 (1.1) 2.8 (1.2) 2.9 (1.8) 2.8 (1.3)
Change score Mean (SD) 1.8 (1.1) 1.9 (1.3) 1.8 (1.6) 1.9 (1.3)
p< 0.0001
CGI-S (Depression)
Baseline score Mean (SD) 3.1 (1.3) 3.3 (1.4) 3.2 (1.0) 3.2 (1.2)
EOS score Mean (SD) 2.0 (1.0) 2.1 (1.3) 2.2 (1.0) 2.1 (1.1)
Change score Mean (SD) 1.2 (1.4) 1.2 (1.4) 0.9 (1.0) 1.1 (1.3)
p< 0.0001
CGI-S (Overall Illness)
Baseline score Mean (SD) 4.7 (0.6) 4.8 (0.7) 4.7 (0.7) 4.7 (0.7)
EOS score Mean (SD) 2.9 (1.1) 2.9 (1.2) 3.0 (1.7) 2.9 (1.3)
Change score Mean (SD) 1.8 (1.0) 2.0 (1.3) 1.7 (1.5) 1.8 (1.2)
p< 0.0001
CDRS-R¼Children’s Depression Rating Scale-Revised; CGAS¼Children’s Global Assessment Scale; CGI-S¼Clinical Global Impressions-












































































Arm I (n = 20)
Arm II (n = 21)
Arm III (n = 19)
Total participants (n = 60)
FIG. 2. Clinical Global Impressions-Improvement (CGI-I) Score at Week 8/ET/LOCF. ET¼ early termination; LOCF¼ last obser-
vation carried forward.
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severity across treatment arms can be found in Table 6. The most
commonly experienced AEs reported during the study are listed in
Table 7.
Four patients had clinically significant changes in laboratory
values during open label treatment with lithium: Increased anti-
thyroglobulin AB and thyroid peroxidase AB (n¼ 1); increased
thyrotropin (n¼ 2); decreased hematocrit, hemoglobin, red blood
cell count, lymphocyte count, and RDW-CV (TEAE of anemia:
n¼ 1); and increased urine specific gravity and leukocyte esterase
(TEAE of urinary tract infection: n¼ 1).
The mean pretreatment thyrotropin concentration was 1.92
(1.05) mIU/L. The mean post-treatment thyrotropin concentration
was 5.28 (3.39) mIU/L ( p< 0.0001). Two patients had a thyro-
tropin concentration greater than 10 mIU/L at week 4, and at week
8, 4 patients had a thyrotropin concentration greater than 10 mIU/L.
There was no overlap between the patients with thyrotropin con-
centration greater than 10 mIU/L at week 4 and those at week 8.
Four patients were described as having a thyroid-related TEAE:
Hypothyroidism (n¼ 1); blood TSH increased (n¼ 3). The mean
pretreatment white blood cell count was 6.50 (1.69)10E9/L, and
the mean post-treatment white blood cell count was 7.97
(2.08)10E9/L ( p< 0.0001). The mean pretreatment neutrophil
concentration was 47.2% (14.7) and the mean post-treatment
neutrophil concentration was 57.2% (12.9) ( p< 0.0001).
AEs and study discontinuations in patients
with lithium levels above 1.4 mEq/L
To reiterate, the 1.4 mEq/L upper limit for lithium level in
the current study was used as a indicator for which dose in-
creases could not occur, rather than a point at which dose was
reduced. Owing to concerns regarding lithium toxicity at higher
serum concentrations, the proportion of patients whose lithium
level at some point exceeded 1.4 mEq/L and the association
with more frequent or serious side effects were examined.
Neither serious AE frequency nor study discontinuations
seemed to rise with lithium serum concentrations above
1.4 mEq/L. These data are shown in Table 8.
Other psychometric measures
Mean (SD) scores at baseline, end of week 4, and end of week 8
for the attention-deficit/hyperactivity disorder Rating Scale-IV,
BPRS for Children, Caregiver Strain Questionnaire, Child Mania
Rating Scale-Parent, Parent General Behavior Inventory-10 Item
Mania Scale, Irritability, Depression, and Anxiety, Nisonger Child
Behavior Rating Form-Typical IQ Version, and Pediatric Anxiety
Rating Scale are summarized in Table 9. Of note, treatment with
lithium was associated with a statistically significant improvement
on every subscale except for organicity ( p¼ 0.56) on the BPRS for
Children. Analyses of the 10 subscales of the Family Environment
Scale (data not presented) showed no significant improvement in
family functioning after 8 weeks of treatment with lithium. On the
Social Adjustment Inventory for Children and Adolescents (data
not presented), significant reductions in baseline scores for school
behavior problems, spare time problems, problems with siblings,
and problems with parents were noted at the end of week 8 (all
p< 0.05).
Table 6. Severity of Treatment-Emergent Adverse Events
Treatment Arm
Arm I Arm II Arm III Total participants




20 (100.0%) 21 (100.0%) 18 (94.7%) 59 (98.3%)
Mild 6 (30.0%) 8 (38.1%) 8 (42.1%) 22 (36.7%)
Moderate 8 (40.0%) 5 (23.8%) 8 (42.1%) 21 (35.0%)
Severe 6 (30.0%) 8 (38.1%) 2 (10.5%) 16 (26.7%)
TEAE¼ treatment-emergent adverse event.
Table 7. Most Frequently Occurring (10% of Total
Patients) Treatment-Emergent Adverse Events





Abdominal pain upper 16 (26.7%)
Abdominal pain 12 (20.0%)






Coordination abnormal 6 (10.0%)







Initial Insomnia 7 (11.7%)
Metabolism and nutrition disorders
Decreased appetite 11 (18.3%)
Increased appetite 9 (15.0%)
Renal and urinary disorders
Pollakiuria 17 (28.3%)
Skin and subcutaneous disorders
Rash 8 (13.3%)
Respiratory, thoracic and mediastinal disorders
Nasal congestion 7 (11.7%)
Eye disorders
Vision blurred 6 (10.0%)
Musculoskeletal and connective tissue disorders
Back pain 6 (10.0%)
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Discussion
To develop an empirically based dosing paradigm, three dif-
ferent strategies with increasing starting doses and two different
rates of escalation were employed. The more rapid dose escalation
paradigm in Arm III was both effective and tolerable. However,
despite the substantive proportion (61.1%) of mid-week upward
dosing increases that occurred during the first week of treatment,
most dosing increases (72.2%) that occurred in the middle of the
second week of treatment were not subsequently maintained. For
this reason, treating patients in a similar fashion to what was used in
Arm III appears, with the exception of having mid-week dosing
increases after week 1, to be a relatively effective means by which
to achieve therapeutic lithium doses.
This protocol employed a strategy to determine a maximally tol-
erated lithium dose, rather than treat patients within a therapeutic
range based on adult data. Although data from this study help provide
information about the upper limits of therapeutic lithium concentra-
tions in youths, this study does not help answer the question of what a
minimally effective dose of lithium in youth might be.
The maximum allowable lithium serum concentration, above
which further dose increases could not occur in this trial (1.4 mEq/L),
is a concentration higher than normally seen in prior pediatric studies
(Findling et al. 2003; Kafantaris et al. 2003; Pavuluri et al. 2004;
Kowatch et al. 2007). This approach was used to determine whether
the upper limits of therapeutic levels reported in adults were tolerable
in children and adolescents. In this study, using the 1.4 mEq/L pa-
rameter as a stopping criterion for subsequent dose increases ap-
peared to be associated with an appropriate degree of safety.
Overall, lithium was well tolerated. Few patients discontinued
treatment as a result of medication-related adverse effects. Further,
the most common side effects that were experienced were ex-
pected. As it has been reported that treatment with lithium is as-
sociated with significant rates of thyrotropin elevation in children
and adolescents with bipolar disorder (Gracious et al. 2004), thy-
rotropin levels were monitored. Overall, mean thyrotropin levels
increased after 8 weeks of open-label treatment with lithium. In
addition, six patients experienced putatively significant increases
(10 mIU/L) in thyrotropin levels. Whether or not these elevations
would be sustained or magnified if the study was extended beyond
8 weeks remains to be seen.
Data from this relatively large, open-label study of lithium
monotherapy in pediatric outpatients adds to the extant literature
(Findling and Pavuluri 2008) that suggests that lithium may be
useful in the treatment of BP-I in children and adolescents. Lithium
monotherapy was generally associated with salutary effects. Re-
gardless of starting dose and dosing strategy, most patients expe-
rienced a significant improvement in mood symptoms. In fact,
slightly more than half of the patients were considered to be re-
sponders after 8 weeks of open-label treatment with lithium.
Table 8. Adverse Events and Study Discontinuations in Patients with Lithium Level >1.4 mEq/L
Arm I Arm II Arm III Total
Lithium level N AE SAE ET N AE SAE ET N AE SAE ET N AE SAE ET
>1.4 mEq/L 8 8 0 1 5 5 0 0 7 6 0 3 20 19 0 4
1.4 mEq/L 12 12 5 4 17 16 0 8 12 12 1 4 41 40 6 16
Total 20 20 5 5 22 21 0 8 19 18 1 7 61 59 6 20
AE¼ adverse event; SAE¼ serious adverse event; ET¼ early termination.
Table 9. Psychometric Measure Scores
Baseline End of week 4 Week 8/ET/LOCF
Instrument Mean (SD) Mean (SD) p Mean (SD) p
ADHD Rating Scale-IV (ARS-IV)
Total score 34.7 (11.7) 28.3 (12.2) 0.0002 29.4 (11.8) 0.0013
Inattention 18.7 (6.2) 16.0 (6.0) 0.0022 16.7 (5.7) 0.0213
Hyperactivity-Impulsivity 16.0 (6.6) 12.4 (6.9) 0.0003 12.7 (7.2) 0.0001
Brief Psychiatric Rating Scale for Children (BPRS-C)
Total score 33.9 (9.5) 18.4 (10.3) <.0001 16.5 (11.0) <0.0001
Caregiver Strain Questionnaire (CSQ)
Total score 66.0 (16.6) N/A N/A 56.6 (19.8) 0.0029
Child Mania Rating Scale-Parent Report (CMRS-P)
Total score 27.4 (10.6) 17.7 (10.0) <0.0001 16.8 (9.8) <0.0001
Parent General Behavior Inventory-10 Item Mania Scale (PGBI-10M)
Total score 17.6 (6.5) 10.4 (7.7) <0.0001 10.8 (7.1) <0.0001
Irritability, depression, and anxiety (IDA)
Total score 9.9 (1.9) 6.5 (3.4) <.0001 5.1 (3.7) <0.0001
Nisonger Child Behavior Rating Form-TIQ (NCBRF-TIQ)
Conduct Problem 18.3 (9.0) 13.3 (9.6) 0.0001 11.3 (9.9) <0.0001
ADHD-Total 22.3 (7.3) 17.4 (7.6) 0.0002 16.9 (7.7) <0.0001
Pediatric Anxiety Rating Scale (PARS)
Total score with five items 5.9 (7.9) 3.9 (7.2) 0.0091 3.9 (6.1) 0.0031
LOCF¼ last observation carried forward; ET¼ early termination.
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However, similar to what has been reported in other monotherapy
studies in pediatric BP-I (Tohen et al. 2007; Findling et al. 2009;
Haas et al. 2009), a majority of the patients did not meet criteria for
remission.
This study is primarily limited by its open uncontrolled design,
brevity, and relatively small sample size. In fact, the rate of re-
sponse may be inflated owing to the open nature of this trial. An-
other limitation is inherent to the fact that this is an outpatient trial.
Specifically, the lithium levels that were ascertained may not have
been fully accurate, as timing of last dose and medication adher-
ence were based on parent/patient report and not direct clinician
observation. Despite this shortcoming, an examination revealed
that the daily lithium dose was highly correlated with serum con-
centration (Pearson correlation coefficient: n¼ 361 pairs, r¼ 0.51,
p< 0.0001). Finally, because this trial studied only the acute
treatment of pediatric mania, conclusions may not be generated as
to whether or not lithium has promise as a form of maintenance
pharmacotherapy in children and adolescents with BP-I.
Conclusions
Perhaps most notably, the results of this study provide a readily
generalizable evidence-based strategy for the dosing of lithium in
pediatric patients. Based on these results, a dosing paradigm in
which patients begin treatment with lithium at a dose of 300 mg
thrice daily, followed by 300 mg weekly increases (with an addi-
tional 300 mg increase during the first week) until a priori stopping
criteria are met, will be used in an upcoming randomized, double-
blind, placebo-controlled trial of lithium in pediatric BP-I.
Clinical Significance
This exploratory study obtained data that provide evidence-
based dosing strategies for lithium in children and adolescents
suffering from BP-I. Lithium was, in general, well-tolerated and
associated with significant symptom amelioration in children and
adolescents with BP-I. However, as reported with other drug
monotherapy studies, remission was not achieved in most patients.
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